n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide has been researched along with etifoxine in 1 studies
Studies (n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide) | Trials (n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide) | Recent Studies (post-2010) (n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide) | Studies (etifoxine) | Trials (etifoxine) | Recent Studies (post-2010) (etifoxine) |
---|---|---|---|---|---|
73 | 0 | 30 | 72 | 9 | 41 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Biswas, L; Dhillon, B; Graham, A; Shu, X; Zhou, X | 1 |
1 other study(ies) available for n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide and etifoxine
Article | Year |
---|---|
Retinal pigment epithelium cholesterol efflux mediated by the 18 kDa translocator protein, TSPO, a potential target for treating age-related macular degeneration.
Topics: Biological Transport; Carrier Proteins; Cells, Cultured; Cholesterol; Humans; Indoleacetic Acids; Ligands; Lipoproteins, LDL; Macular Degeneration; Mitochondria; Molecular Targeted Therapy; Oxazines; Oxidative Stress; Pancreatic Elastase; Purines; Reactive Oxygen Species; Receptors, GABA; Retinal Pigment Epithelium | 2017 |